Form 4: Lixte Biotechnology Director Yun Yen Receives Stock Options in Lieu of Cash Compensation

Director Yun Yen received 8,777 stock options in Lixte Biotechnology in lieu of quarterly cash compensation on March 31, 2025.

Summary

• On April 1, 2025, Yun Yen, a director of Lixte Biotechnology Holdings, Inc., filed a Form 4.
• The form reports a transaction that occurred on March 31, 2025, where Yen was granted 8,777 stock options to purchase common stock at a price of $1.21 per share.
• These options vest immediately and expire on March 31, 2030.
• The grant was in lieu of quarterly cash compensation due to Yen under the Board Compensation Plan.
• Yen also directly owns options to purchase common stock at various prices and expiration dates, as well as warrants to purchase common stock indirectly through Sino-American Cancer FDD.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options aligns the director's interests with shareholders, which is generally viewed favorably. There are no explicitly negative aspects mentioned in the filing.

Positives

• The receipt of stock options in lieu of cash compensation can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Management Comments

• The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry depending on the size and stage of the company.
• Stock options are frequently used to align director incentives with shareholder value creation, similar to practices at companies like Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, Form 4, director, Lixte Biotechnology, compensation, Yun Yen, options, warrants